A review on the cleavage priming of the spike protein on coronavirus by angiotensin-converting enzyme-2 and furin

Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China

Huang, C., Wang, Y., Li, X., Ren, L., Zhao, J., Hu, Y., Zhang, L., Fan, G., Xu, J., Gu, X., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30183-5 · Cited by 48,884

SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor

Hoffmann, M., Kleine-Weber, H., Schroeder, S., Krüger, N., Herrler, T., Erichsen, S., Schiergens, T. S., Herrler, G., Wu, N.-H., Nitsche, A., et al. (2020) · Cell · doi:10.1016/j.cell.2020.02.052 · Cited by 20,286

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and coronavirus disease-2019 (COVID-19): The epidemic and the challenges

Lai, C.-C., Shih, T.-P., Ko, W.-C., Tang, H.-J., & Hsueh, P.-R. (2020) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2020.105924 · Cited by 6,068

Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus

Li, W., Moore, M. J., Vasilieva, N., Sui, J., Wong, S. K., Berne, M. A., Somasundaran, M., Sullivan, J. L., Luzuriaga, K., Greenough, T. C., et al. (2003) · Nature · doi:10.1038/nature02145 · Cited by 5,923

A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS coronavirus–induced lung injury

Kuba, K., Imai, Y., Rao, S., Gao, H., Guo, F., Guan, B., Huan, Y., Yang, P., Zhang, Y., Deng, W., et al. (2005) · Nature Medicine · doi:10.1038/nm1267 · Cited by 3,445

The reproductive number of COVID-19 is higher compared to SARS coronavirus

Liu, Y., Gayle, A. A., Wilder‐Smith, A., & Rocklöv, J. (2020) · Journal of Travel Medicine · doi:10.1093/jtm/taaa021 · Cited by 3,243

Functional assessment of cell entry and receptor usage for SARS-CoV-2 and other lineage B betacoronaviruses

Letko, M., Marzi, A., & Munster, V. (2020) · Nature Microbiology · doi:10.1038/s41564-020-0688-y · Cited by 3,109

Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection?

Fang, L., Karakiulakis, G., & Roth, M. (2020) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(20)30116-8 · Cited by 2,947

Structure, Function, and Evolution of Coronavirus Spike Proteins

Li, F. (2016) · Annual Review of Virology · doi:10.1146/annurev-virology-110615-042301 · Cited by 2,740

Angiotensin-converting enzyme 2 (ACE2) as a SARS-CoV-2 receptor: molecular mechanisms and potential therapeutic target

Zhang, H., Penninger, J. M., Li, Y., Zhong, N., & Slutsky, A. S. (2020) · Intensive Care Medicine · doi:10.1007/s00134-020-05985-9 · Cited by 2,684

Scaffold morphing of arbidol (umifenovir) in search of multi-targeting therapy halting the interaction of SARS-CoV-2 with ACE2 and other proteases involved in COVID-19

Choudhary, S., & Silakari, O. (2020) · Virus Research · doi:10.1016/j.virusres.2020.198146 · Cited by 47

nCOV-19 peptides mass fingerprinting identification, binding, and blocking of inhibitors flavonoids and anthraquinone ofMoringa oleiferaand hydroxychloroquine

Hamza, M., Ali, A., Khan, S., Ahmed, S., Attique, Z., Rehman, S. U., Khan, A. H., Ali, H., Rizwan, M., Munir, A., et al. (2020) · Journal of Biomolecular Structure and Dynamics · doi:10.1080/07391102.2020.1778534 · Cited by 46

Genomics insights of SARS-CoV-2 (COVID-19) into target-based drug discovery

Chellapandi, P., & Saranya, S. V. (2020) · Medicinal Chemistry Research · doi:10.1007/s00044-020-02610-8 · Cited by 46

Quantitative assays reveal cell fusion at minimal levels of SARS-CoV-2 spike protein and fusion from without

Theuerkauf, S. A., Michels, A., Riechert, V., Maier, T. J., Flory, E., Cichutek, K., & Buchholz, C. J. (2021) · iScience · doi:10.1016/j.isci.2021.102170 · Cited by 50

Immunotoxic role of organophosphates: An unseen risk escalating SARS-CoV-2 pathogenicity

Rajak, P., Ganguly, A., Sarkar, S., Mandi, M., Dutta, M., Podder, S., Khatun, S., & Roy, S. (2021) · Food and Chemical Toxicology · doi:10.1016/j.fct.2021.112007 · Cited by 46

Essentials in saline pharmacology for nasal or respiratory hygiene in times of COVID-19

Huijghebaert, S., Hoste, L., & Vanham, G. (2021) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-021-03102-3 · Cited by 46

COVID-19 Infection in Children and Infants: Current Status on Therapies and Vaccines

Malcangi, G., Inchingolo, A. D., Inchingolo, A. M., Piras, F., Settanni, V., Garofoli, G., Palmieri, G., Ceci, S., Patano, A., Mancini, A., et al. (2022) · Children · doi:10.3390/children9020249 · Cited by 49

Potential inhibitors of SARS-cov-2 RNA dependent RNA polymerase protein: molecular docking, molecular dynamics simulations and MM-PBSA analyses

Elkarhat, Z., Charoute, H., Elkhattabi, L., Barakat, A., & Rouba, H. (2020) · Journal of Biomolecular Structure and Dynamics · doi:10.1080/07391102.2020.1813628 · Cited by 41

Inhibition Potencies of Phytochemicals Derived from Sesame Against SARS-CoV-2 Main Protease: A Molecular Docking and Simulation Study

Kumar, A., Mishra, D. C., Angadi, U. B., Yadav, R., Rai, A. K., & Kumar, D. (2021) · Frontiers in Chemistry · doi:10.3389/fchem.2021.744376 · Cited by 41

Recent advances in the development of allosteric protein tyrosine phosphatase inhibitors for drug discovery

Elhassan, R. M., Hou, X., & Fang, H. (2021) · Medicinal Research Reviews · doi:10.1002/med.21871 · Cited by 40

Current status and strategic possibilities on potential use of combinational drug therapy against COVID-19 caused by SARS-CoV-2

Siddiqui, A. J., Jahan, S., Ashraf, S. A., Alreshidi, M. M., Ashraf, M. S., Patel, M. B., Snoussi, M., Singh, R., & Adnan, M. (2020) · Journal of Biomolecular Structure and Dynamics · doi:10.1080/07391102.2020.1802345 · Cited by 41

The 15-Months Clinical Experience of SARS-CoV-2: A Literature Review of Therapies and Adjuvants

Inchingolo, A. D., Dipalma, G., Inchingolo, A. M., Malcangi, G., Santacroce, L., D’Oria, M. T., Isacco, C. G., Bordea, I. R., Candrea, S., Scarano, A., et al. (2021) · Antioxidants · doi:10.3390/antiox10060881 · Cited by 54

Postbiotics as potential promising tools for SARS-CoV-2 disease adjuvant therapy

Khani, N., Soleimani, R. A., Noorkhajavi, G., Soleimani, A. A., Abbasi, A., & Rad, A. H. (2022) · Journal of Applied Microbiology · doi:10.1111/jam.15457 · Cited by 39

SARS-CoV-2 Disease through Viral Genomic and Receptor Implications: An Overview of Diagnostic and Immunology Breakthroughs

Inchingolo, A. D., Inchingolo, A. M., Bordea, I. R., Malcangi, G., Xhajanka, E., Scarano, A., Lorusso, F., Farronato, M., Tartaglia, G. M., Isacco, C. G., et al. (2021) · Microorganisms · doi:10.3390/microorganisms9040793 · Cited by 43

A second functional furin site in the SARS-CoV-2 spike protein

Zhang, Y., Zhang, L., Wu, J., Yu, Y., Liu, S., Li, T., Li, Q., Ding, R., Wang, H., Nie, J., et al. (2021) · Emerging Microbes & Infections · doi:10.1080/22221751.2021.2014284 · Cited by 42

Current and Future Perspectives on the COVID-19 Vaccine: A Scientometric Review

Noruzi, A., Gholampour, B., Gholampour, S., Jafari, S., Farshid, R., Stanek, A., & Saboury, A. A. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11030750 · Cited by 41

microRNAs as new possible actors in gender disparities of Covid‐19 pandemic

Pontecorvi, G., Bellenghi, M., Ortona, E., & Carè, A. (2020) · Acta Physiologica · doi:10.1111/apha.13538 · Cited by 37

In silico analysis and identification of promising hits against 2019 novel coronavirus 3C-like main protease enzyme

Chatterjee, S., Maity, A., Chowdhury, S., Islam, M. A., Muttinini, R. K., & Sen, D. (2020) · Journal of Biomolecular Structure and Dynamics · doi:10.1080/07391102.2020.1787228 · Cited by 38

Natural and Nature-Derived Products Targeting Human Coronaviruses

Vougogiannopoulou, K., Corona, A., Tramontano, E., Alexis, Μ. N., & Skaltsounis, A. (2021) · Molecules · doi:10.3390/molecules26020448 · Cited by 39

Plant‐derived chemicals as potential inhibitors of SARS‐CoV ‐2 main protease ( 6LU7 ), a virtual screening study

Sisakht, M., Mahmoodzadeh, A., & Darabian, M. (2021) · Phytotherapy Research · doi:10.1002/ptr.7041 · Cited by 37

Rapid diagnostics of coronavirus disease 2019 in early stages using nanobiosensors: Challenges and opportunities

Sharifi, M., Hasan, A., Haghighat, S., Taghizadeh, A., Attar, F., Bloukh, S. H., Edis, Z., Xue, M., Khan, S., & Falahati, M. (2020) · Talanta · doi:10.1016/j.talanta.2020.121704 · Cited by 38

Evaluation and characterization of HSPA5 (GRP78) expression profiles in normal individuals and cancer patients with COVID-19

Fu, J., Wei, C., He, J., Zhang, L., Zhou, J., Balaji, K. S., Shen, S., Peng, J., Sharma, A., & Fu, J. (2021) · International Journal of Biological Sciences · doi:10.7150/ijbs.54055 · Cited by 35

The expression level of angiotensin-converting enzyme 2 determines the severity of COVID-19: lung and heart tissue as targets

Babadaei, M. M. N., Hasan, A., Bloukh, S. H., Edis, Z., Sharifi, M., Kachooei, E., & Falahati, M. (2020) · Journal of Biomolecular Structure and Dynamics · doi:10.1080/07391102.2020.1767211 · Cited by 39

A computational drug repurposing approach in identifying the cephalosporin antibiotic and anti-hepatitis C drug derivatives for COVID-19 treatment

Kumar, R., Kumar, V., & Lee, K. W. (2020) · Computers in Biology and Medicine · doi:10.1016/j.compbiomed.2020.104186 · Cited by 35

Platelet Activation and Plasma Levels of Furin Are Associated With Prognosis of Patients With Coronary Artery Disease and COVID-19

Langnau, C., Rohlfing, A., Gekeler, S., Günter, M., Pöschel, S., Petersen-Uribe, Á., Jaeger, P., Avdiu, A., Harm, T., Kreißelmeier, K., et al. (2021) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.120.315698 · Cited by 34

An exhaustive comprehension of the role of herbal medicines in Pre- and Post-COVID manifestations

Prajapati, S. K., Malaiya, A., Mishra, G., Jain, D., Kesharwani, P., Mody, N., Ahmadi, A., Paliwal, R., & Jain, A. (2022) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2022.115420 · Cited by 37

Computational investigation of potential inhibitors of novel coronavirus 2019 through structure-based virtual screening, molecular dynamics and density functional theory studies

Mishra, S. S., Ranjan, S., Sharma, C. S., Singh, H. P., Kalra, S., & Kumar, N. (2020) · Journal of Biomolecular Structure and Dynamics · doi:10.1080/07391102.2020.1791957 · Cited by 35

Berries anthocyanins as potential SARS-CoV–2 inhibitors targeting the viral attachment and replication; molecular docking simulation

Messaoudi, O., Gouzi, H., El-hoshoudy, A. N., Benaceur, F., Patel, C., Goswami, D., Boukerouis, D., & Bendahou, M. (2021) · Egyptian Journal of Petroleum · doi:10.1016/j.ejpe.2021.01.001 · Cited by 33

Kidney Injury in COVID-19: Epidemiology, Molecular Mechanisms and Potential Therapeutic Targets

Teixeira, J. P., Barone, S., Zahedi, K. A., & Soleimani, M. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23042242 · Cited by 34

Photonics enabled intelligence system to identify SARS-CoV 2 mutations

Taha, B. A., Al-Jubouri, Q., Mashhadany, Y. I. M. A., Zan, M. S. D., Bakar, A. A. A., Fadhel, M. M., & Arsad, N. (2022) · Applied Microbiology and Biotechnology · doi:10.1007/s00253-022-11930-1 · Cited by 32

Identification of potential drug candidates to combat COVID-19: a structural study using the main protease (mpro) of SARS-CoV-2

Sharma, P., Viswanathan, V., Pant, P., Sharma, M., Vikram, N. K., Kaur, P., Singh, T. P., & Sharma, S. (2020) · Journal of Biomolecular Structure and Dynamics · doi:10.1080/07391102.2020.1798286 · Cited by 33

Antiretroviral drug activity and potential for pre-exposure prophylaxis against COVID-19 and HIV infection

Copertino, D. C., Lima, B. C. C., Duarte, R. R. R., Powell, T. R., Ormsby, C. E., Wilkin, T. J., Gulick, R. M., Rougvie, M. D. M., & Nixon, D. F. (2021) · Journal of Biomolecular Structure and Dynamics · doi:10.1080/07391102.2021.1901144 · Cited by 28

Identification and characterization of novel RdRp and Nsp15 inhibitors for SARS-COV2 using computational approach

Barage, S. H., Karthic, A., Bavi, R., Desai, N. S., Kumar, R., Kumar, V., & Lee, K. W. (2020) · Journal of Biomolecular Structure and Dynamics · doi:10.1080/07391102.2020.1841026 · Cited by 28

Probing the functional and therapeutic properties of postbiotics in relation to their industrial application

Asif, A., Afzaal, M., Shahid, H., Saeed, F., Ahmed, A., Shah, Y. A., Ejaz, A., Ghani, S., Ateeq, H., & Khan, M. R. (2023) · Food Science & Nutrition · doi:10.1002/fsn3.3465 · Cited by 31

In Silico Approaches for Novel Drug Discovery Against Coronavirus by Employing the Hybrid Molecular Technique: A Review

Mohsin, N. U. A., Irfan, M., & Aamir, M. N. (2021) · Journal of Computational Biophysics and Chemistry · doi:10.1142/s2737416521300017 · Cited by 28

1,2,4 triazolo[1,5-a] pyrimidin-7-ones as novel SARS-CoV-2 Main protease inhibitors: In silico screening and molecular dynamics simulation of potential COVID-19 drug candidates

Kavitha, K., Sivakumar, S., & Ramesh, B. (2020) · Biophysical Chemistry · doi:10.1016/j.bpc.2020.106478 · Cited by 28

COVID-19 and Dentistry in 72 Questions: An Overview of the Literature

Derruau, S., Bouchet, J., Nassif, A., Baudet, A., Yasukawa, K., Lorimier, S., Prêcheur, I., Bloch‐Zupan, A., Pellat, B., Chardin, H., et al. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10040779 · Cited by 30

Computational insights into binding mechanism of drugs as potential inhibitors against SARS-CoV-2 targets

Arooj, M., Shehadi, I. A., Nassab, C. N., & Mohamed, A. A. M. (2021) · Chemical Papers · doi:10.1007/s11696-021-01843-0 · Cited by 28

Intrinsically Disordered Proteins: Perspective on COVID-19 Infection and Drug Discovery

Tenchov, R., & Zhou, Q. A. (2022) · ACS Infectious Diseases · doi:10.1021/acsinfecdis.2c00031 · Cited by 29

Identification of a potential SARS-CoV2 inhibitor via molecular dynamics simulations and amino acid decomposition analysis

Razzaghi‐Asl, N., Ebadi, A., Shahabipour, S., & Gholamin, D. (2020) · Journal of Biomolecular Structure and Dynamics · doi:10.1080/07391102.2020.1797536 · Cited by 27

Union is strength: antiviral and anti-inflammatory drugs for COVID-19

Naveja, J. J., Madariaga‐Mazón, A., Flores‐Murrieta, F. J., Granados‐Montiel, J., Maradiaga‐Ceceña, M. A., Duarte-Alaniz, V., Maldonado-Rodriguez, M., García-Morales, J., Senosiain, J. P., & Martínez‐Mayorga, K. (2020) · Drug Discovery Today · doi:10.1016/j.drudis.2020.10.018 · Cited by 29

Alterations in platelets during SARS-CoV-2 infection

Brambilla, M., Canzano, P., Becchetti, A., Tremoli, E., & Camera, M. (2021) · Platelets · doi:10.1080/09537104.2021.1962519 · Cited by 27

Antioxidant, Anti-inflammatory, and Immunomodulatory Roles of Nonvitamin Antioxidants in Anti-SARS-CoV-2 Therapy

Pisoschi, A. M., Iordache, F., Stanca, L., Gâjâilă, I., Ghimpeţeanu, O. M., Geicu, O. I., Bîlteanu, L., & Șerban, A. I. (2022) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.2c01134 · Cited by 30

Bacterial protein azurin and derived peptides as potential anti-SARS-CoV-2 agents: insights from molecular docking and molecular dynamics simulations

Sasidharan, S., Selvaraj, C., Singh, S. K., Dubey, V. K., Kumar, S., Fialho, A. M., & Saudagar, P. (2020) · Journal of Biomolecular Structure and Dynamics · doi:10.1080/07391102.2020.1787864 · Cited by 26

Structural insight to hydroxychloroquine-3C-like proteinase complexation from SARS-CoV-2: inhibitor modelling study through molecular docking and MD-simulation study

Mukherjee, S., Dasgupta, S., Adhikary, T., Adhikari, U., & Panja, S. S. (2020) · Journal of Biomolecular Structure and Dynamics · doi:10.1080/07391102.2020.1804458 · Cited by 25

Is Spironolactone the Preferred Renin–Angiotensin–Aldosterone Inhibitor for Protection Against COVID-19?

Wilcox, C. S., & Pitt, B. (2020) · Journal of Cardiovascular Pharmacology · doi:10.1097/fjc.0000000000000960 · Cited by 25

Additional Positive Electric Residues in the Crucial Spike Glycoprotein S Regions of the New SARS-CoV-2 Variants

Pawłowski, P. H. (2021) · Infection and Drug Resistance · doi:10.2147/idr.s342068 · Cited by 25

Mapping COVID-19 related research from Saudi Arabia, a scoping review

AlMaghlouth, I. A., Islam, T., Alamro, N., Alsultan, A. S., Alfadda, A. A., Al‐Muhsen, S., Almasry, A., Almadi, M. A., Hersi, A. S., & BaHammam, A. S. (2020) · Saudi Medical Journal · doi:10.15537/smj.2020.8.25163 · Cited by 24

COVID-19: Physiopathology and Targets for Therapeutic Intervention

de Almeida, J. O., de Oliveira, V. R. T., Avelar, J. L. D. S., Moita, B. S., & Lima, L. M. (2020) · Revista Virtual de Química · doi:10.21577/1984-6835.20200115 · Cited by 26

Circulating furin, IL-6, and presepsin levels and disease severity in SARS-CoV-2–infected patients

Koçyiğit, A., Söğüt, Ö., Durmuş, E., Kanımdan, E., Güler, E. M., Kaplan, O., Yenigun, V. B., Eren, C., Özman, Z., & Yasar, O. (2021) · Science Progress · doi:10.1177/00368504211026119 · Cited by 24

Antimicrobial peptides: A promising tool to combat multidrug resistance in SARS CoV2 era

Saini, J., Kaur, P., Malik, N., Lakhawat, S. S., & Sharma, P. K. (2022) · Microbiological Research · doi:10.1016/j.micres.2022.127206 · Cited by 24

Virtual Screening of Orally Active Lead Compounds of Pearl Millet and Their Structural Activity Against Target Protein of COVID-19

Shukla, A. K., & Kumar, A. (2023) · Russian Journal of Bioorganic Chemistry · doi:10.1134/s1068162023080058 · Cited by 24

Molecular docking, molecular dynamics simulation, and ADMET analysis of levamisole derivatives against the SARS-CoV-2 main protease (MPro)

Khatabi, K. E., Aanouz, I., Alaqarbeh, M., Ajana, M. A., Lakhlifi, T., & Bouachrıne, M. (2021) · Bioimpacts · doi:10.34172/bi.2021.22143 · Cited by 22

Structural variations and expression profiles of the SARS‐CoV‐2 host invasion genes in lung cancer

Sağkan, R. I., & Akın, D. F. (2020) · Journal of Medical Virology · doi:10.1002/jmv.26107 · Cited by 21

In Silico Exploration of Phytoconstituents From Phyllanthus emblica and Aegle marmelos as Potential Therapeutics Against SARS-CoV-2 RdRp

Pandey, K., Lokhande, K. B., Swamy, K. V., Nagar, S., & Dake, M. S. (2021) · Bioinformatics and Biology Insights · doi:10.1177/11779322211027403 · Cited by 21

Drug repurposing strategies and key challenges for COVID-19 management

Mule, S., Singh, A., Greish, K. F., Sahebkar, A., Kesharwani, P., & Shukla, R. (2021) · Journal of drug targeting · doi:10.1080/1061186x.2021.2013852 · Cited by 22

Structure of Human TMPRSS2 in Complex with SARS-CoV-2 Spike Glycoprotein and Implications for Potential Therapeutics

Vankadari, N., Ketavarapu, V., Sasikala, M., Vishnubhotla, R., Reddy, D. N., & Ghosal, D. (2022) · The Journal of Physical Chemistry Letters · doi:10.1021/acs.jpclett.2c00967 · Cited by 21

Biosensor Detection of COVID-19 in Lung Cancer: Hedgehog and Mucin Signaling Insights

Marwah, H., Pant, J., Yadav, J., Shah, K., & Dewangan, H. K. (2023) · Current Pharmaceutical Design · doi:10.2174/0113816128276948231204111531 · Cited by 22

Smoking Status and Factors associated with COVID-19 In-Hospital Mortality among US Veterans

Razjouyan, J., Helmer, D. A., Lynch, K. E., Hanania, N. A., Klotman, P. E., Sharafkhaneh, A., & Amos, C. I. (2021) · Nicotine & Tobacco Research · doi:10.1093/ntr/ntab223 · Cited by 21

Infection of Human Cells by SARS-CoV-2 and Molecular Overview of Gastrointestinal, Neurological, and Hepatic Problems in COVID-19 Patients

Rahban, M., Stanek, A., Hooshmand, A., Khamineh, Y., Ahi, S., Kazim, S. N., Ahmad, F., Muronetz, V. I., Abousenna, M. S., Zolghadri, S., et al. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10214802 · Cited by 20

The interaction of the bioflavonoids with five SARS-CoV-2 proteins targets: An in silico study

Mishra, G. P., Bhadane, R. N., Panigrahi, D., Amawi, H. A., Asbhy, C. R., & Tiwari, A. K. (2021) · Computers in Biology and Medicine · doi:10.1016/j.compbiomed.2021.104464 · Cited by 20

Natural compounds may contribute in preventing SARS-CoV-2 infection: a narrative review

Bizzoca, M. E., Leuci, S., Mignogna, M. D., Muzio, E. L., Caponio, V. C. A., & Muzio, L. L. (2022) · Food Science and Human Wellness · doi:10.1016/j.fshw.2022.04.005 · Cited by 20

COVID-19 Infection in Children, Infants and Pregnant Subjects: An Overview of Recent Insights and Therapies

Malcangi, G., Inchingolo, A. D., Inchingolo, A. M., Santacroce, L., Marinelli, G., Mancini, A., Vimercati, L., Maggiore, M. E., D’Oria, M. T., Hazballa, D., et al. (2021) · Microorganisms · doi:10.3390/microorganisms9091964 · Cited by 31

Biological effects of COVID-19 on lung cancer: Can we drive our decisions

Aramini, B., Masciale, V., Samarelli, A., Tonelli, R., Cerri, S., Clini, E., Stella, F., & Dominici, M. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.1029830 · Cited by 19

Computational investigation for identification of potential phytochemicals and antiviral drugs as potential inhibitors for RNA-dependent RNA polymerase of COVID-19

Singh, J., Malik, D., & Raina, A. (2020) · Journal of Biomolecular Structure and Dynamics · doi:10.1080/07391102.2020.1847688 · Cited by 18

Molecular modeling and simulations of some antiviral drugs, benzylisoquinoline alkaloid, and coumarin molecules to investigate the effects on Mpro main viral protease inhibition

Mir, S. A., Meher, R. K., & Nayak, B. (2023) · Biochemistry and Biophysics Reports · doi:10.1016/j.bbrep.2023.101459 · Cited by 17

SARS-CoV-2 replication and drug discovery

Nazir, F., Kombe, A. J. K., Khalid, Z., Bibi, S., Zhang, H., Wu, S., & Jin, T. (2024) · Molecular and Cellular Probes · doi:10.1016/j.mcp.2024.101973 · Cited by 22

Bioinformatics prediction of B and T cell epitopes within the spike and nucleocapsid proteins of SARS-CoV2

Dawood, R. M., El-Meguid, M. A., Salum, G. M., El-Wakeel, K. H., Shemis, M. A., & Awady, M. K. E. (2020) · Journal of Infection and Public Health · doi:10.1016/j.jiph.2020.12.006 · Cited by 17

Role of Serine Proteases and Host Cell Receptors Involved in Proteolytic Activation, Entry of SARS-CoV-2 and Its Current Therapeutic Options

Dessie, G., & Malik, T. (2021) · Infection and Drug Resistance · doi:10.2147/idr.s308176 · Cited by 18

Potential approaches to combat COVID-19: a mini-review

Sarwar, Z., Ahmad, T., & Kakar, S. J. (2020) · Molecular Biology Reports · doi:10.1007/s11033-020-05988-1 · Cited by 16

The Correlation Between Immune Invasion and SARS-COV-2 Entry Protein ADAM17 in Cancer Patients by Bioinformatic Analysis

Wang, K., Deng, H., Song, B., He, J., Liu, S., Fu, J., Zhang, L., Li, D., Balaji, K. S., Mei, Z., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.923516 · Cited by 16

The Controversy of Renin–Angiotensin-System Blocker Facilitation Versus Countering COVID-19 Infection

Manolis, A. S., Manolis, T. A., Manolis, A. S., & Melita, H. (2020) · Journal of Cardiovascular Pharmacology · doi:10.1097/fjc.0000000000000894 · Cited by 16

Identification of lead compounds from large natural product library targeting 3C-like protease of SARS-CoV-2 using E-pharmacophore modelling, QSAR and molecular dynamics simulation

Elekofehinti, O. O., Iwaloye, O., Molehin, O. R., & Famusiwa, C. D. (2021) · In Silico Pharmacology · doi:10.1007/s40203-021-00109-7 · Cited by 16

Cardiovascular Disease Complicating COVID-19 in the Elderly

Dayaramani, C., Leon, J. D., & Reiss, A. B. (2021) · Medicina · doi:10.3390/medicina57080833 · Cited by 16

Different compounds against Angiotensin-Converting Enzyme 2 (ACE2) receptor potentially containing the infectivity of SARS-CoV-2: an in silico study

Shahbazi, B., Mafakher, L., & Teimoori‐Toolabi, L. (2022) · Journal of Molecular Modeling · doi:10.1007/s00894-022-05059-1 · Cited by 16

Structural aspects of SARS-CoV-2 mutations: Implications to plausible infectivity with ACE-2 using computational modeling approach

Gopi, P., Gurnani, M., Singh, S., Sharma, P., & Pandya, P. (2022) · Journal of Biomolecular Structure and Dynamics · doi:10.1080/07391102.2022.2108901 · Cited by 16

In silico identification of available drugs targeting cell surface BiP to disrupt SARS-CoV-2 binding and replication: Drug repurposing approach

Zhang, Y. J., Greer, R. A., Song, Y., Praveen, H., & Song, Y. (2021) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2021.105771 · Cited by 16

Genetic variants in TMPRSS2 and Structure of SARS-CoV-2 spike glycoprotein and TMPRSS2 complexPreprint

Vishnubhotla, R., Vankadari, N., Ketavarapu, V., Amanchy, R., Avanthi, S. U., Bale, G., Reddy, D. N., & Sasikala, M. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.06.30.179663 · Cited by 16

Insights into structural, vibrational, and chemical shift characteristics, solvents impact (polar and nonpolar) on electronic properties and reactive sites, ADMET predictions, and ligand-protein interactions for antiviral drugs safrole and isosafrole: An in-silico approach

Kumar, A. R., Selvaraj, S., Rajkumar, P. R., Dhanalakshmi, J., Kumar, M., Nagarajan, S. K., Jayaprakash, P., Mol, G. P. S., Awasthi, S., & Pandey, S. K. (2023) · Chemical Physics Impact · doi:10.1016/j.chphi.2023.100443 · Cited by 15

Potential inhibitors of angiotensin converting enzyme 2 receptor of COVID-19 by Corchorus olitorius Linn using docking, molecular dynamics, conceptual DFT investigation and pharmacophore mapping

Mesli, F., Ghalem, M., Daoud, I., & Ghalem, S. (2021) · Journal of Biomolecular Structure and Dynamics · doi:10.1080/07391102.2021.1896389 · Cited by 15

Natural medicinal plant products as an immune-boosters: A possible role to lessen the impact of Covid-19

Islam, S. S., Midya, S., Sinha, S., & Saadi, S. M. A. I. (2021) · Case Studies in Chemical and Environmental Engineering · doi:10.1016/j.cscee.2021.100105 · Cited by 14

Nanoconjugates-Based Stem Cell Therapy for the Management of COVID-19

Desai, D., & Shende, P. K. (2020) · Stem Cell Reviews and Reports · doi:10.1007/s12015-020-10079-6 · Cited by 14

Docking Analysis of Some Bioactive Compounds from Traditional Plants against SARS-CoV-2 Target Proteins

El-Aziz, N. M. A., Khalifa, I., Darwish, A. M. G., Badr, A. N., Aljumayi, H., Hafez, E. S. E., & Shehata, M. G. (2022) · Molecules · doi:10.3390/molecules27092662 · Cited by 14

Plant‐derived compounds as potential leads for new drug development targeting COVID‐19

Liu, L., Kapralov, M. V., & Ashton, M. R. (2024) · Phytotherapy Research · doi:10.1002/ptr.8105 · Cited by 14

Antiviral Potential of Small Molecules Cordycepin, Thymoquinone, and N6, N6-Dimethyladenosine Targeting SARS-CoV-2 Entry Protein ADAM17

He, J., Liu, S., Tan, Q., Liu, Z., Fu, J., Li, T., Wei, C., Liu, X., Mei, Z., Cheng, J., et al. (2022) · Molecules · doi:10.3390/molecules27249044 · Cited by 13

An overview on medicinal plants used for combating coronavirus: Current potentials and challenges

Baker, D. H. A., Hassan, E. M., & Gengaihi, S. E. (2023) · Journal of Agriculture and Food Research · doi:10.1016/j.jafr.2023.100632 · Cited by 12

Evaluation of epidemiology, clinical features, prognosis, diagnosis and treatment outcomes of patients with COVID‐19 in West Azerbaijan Province

Gharebaghi, N., Farshid, S., Boroofeh, B., Nejadrahim, R., Mousavi, J., Dindarian, S., Mohammadi, S., & Valizadeh, R. (2021) · International Journal of Clinical Practice · doi:10.1111/ijcp.14108 · Cited by 10

Interference of Chaga mushroom terpenoids with the attachment of SARS-CoV-2; in silico perspective

Elshemey, W. M., Elfiky, A. A., Ibrahim, I. M., & Elgohary, A. M. (2022) · Computers in Biology and Medicine · doi:10.1016/j.compbiomed.2022.105478 · Cited by 12

A Hypertonic Seawater Nasal Irrigation Solution Containing Algal and Herbal Natural Ingredients Reduces Viral Load and SARS-CoV-2 Detection Time in the Nasal Cavity

Pantazopoulos, I. N., Chalkias, A. F., Miziou, A., Spanos, M., Gerovasileiou, E. S., Rouka, E. C., & Gourgoulianis, K. I. (2023) · Journal of Personalized Medicine · doi:10.3390/jpm13071093 · Cited by 12

Enhanced sampling protocol to elucidate fusion peptide opening of SARS-CoV-2 spike protein

Remington, J. M., McKay, K. T., Ferrell, J. B., Schneebeli, S. T., & Li, J. (2021) · Biophysical Journal · doi:10.1016/j.bpj.2021.05.022 · Cited by 13

[From empiricism to scientific evidence in antiviral treatment in severe cases of coronavirus infection in times of epidemic].

Estella, Á., & Garnacho‐Montero, J. (2020) · PubMed Central · doi:10.1016/j.medin.2020.04.009 · Cited by 12

Computer Aided Structure-Based Drug Design of Novel SARS-CoV-2 Main Protease Inhibitors: Molecular Docking and Molecular Dynamics Study

Kolybalov, D. S., Kadtsyn, E. D., & Arkhipov, S. G. (2024) · Computation · doi:10.3390/computation12010018 · Cited by 16

COVID-19, A new challenge in the dental practice

Silvestre, F., Martínez-Herrera, M., Márquez‐Arrico, C. F., & Silvestre‐Rangil, J. (2021) · Journal of Clinical and Experimental Dentistry · doi:10.4317/jced.57362 · Cited by 10

SARS-CoV-2 and COVID-19 Research Trend during the First Two Years of the Pandemic in the United Arab Emirates: A PRISMA-Compliant Bibliometric Analysis

Al‐Omari, B., Ahmad, T., & Al‐Rifai, R. H. (2022) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph19137753 · Cited by 10

Human Acute and Chronic Viruses: Host-Pathogen Interactions and Therapeutics

Hoffman, M., Chigbu, D. I., Crumley, B. L., Sharma, R. K., Pustylnikov, S., Crilley, T. A., Ginwala, R., Loonawat, R., Joseph, J., Sales, D., et al. (2020) · Springer eBooks · doi:10.1007/978-3-030-33946-3_1 · Cited by 10

Full-Length Computational Model of the SARS-CoV-2 Spike Protein and Its Implications for a Viral Membrane Fusion Mechanism

Nishima, W., & Kulik, M. (2021) · Viruses · doi:10.3390/v13061126 · Cited by 10

SARS-CoV-2 Antibody Neutralization Assay Platforms Based on Epitopes Sources: Live Virus, Pseudovirus, and Recombinant S Glycoprotein RBD

Septisetyani, E. P., Prasetyaningrum, P. W., Anam, K., & Santoso, A. (2021) · Immune Network · doi:10.4110/in.2021.21.e39 · Cited by 11

Suggestion of active 3-chymotrypsin like protease (3CL Pro ) inhibitors as potential anti-SARS-CoV-2 agents using predictive QSAR model based on the combination of ALASSO with an ANN model

Mozafari, Z., Chamjangali, M. A., Arashi, ‎., & Goudarzi, N. (2021) · SAR and QSAR in environmental research · doi:10.1080/1062936x.2021.1975167 · Cited by 10

Computational study for identifying promising therapeutic agents of hydroxychloroquine analogues against SARS‐CoV‐2

Prasanth, D., Murahari, M., Chandramohan, V., Guntupalli, C., & Rao, A. L. (2021) · Journal of Biomolecular Structure and Dynamics · doi:10.1080/07391102.2021.1965027 · Cited by 9

Atomistic insight into 2D COFs as antiviral agents against SARS-CoV-2

Jahromi, A. M., Solhjoo, A., Ghasemi, M., Khedri, M., Maleki, R., & Tayebi, L. (2021) · Materials Chemistry and Physics · doi:10.1016/j.matchemphys.2021.125382 · Cited by 9

A novel antibody against the furin cleavage site of SARS-CoV-2 spike protein: Effects on proteolytic cleavage and ACE2 binding

Spelios, M. G., Capanelli, J. M., & Li, A. W. (2022) · Immunology Letters · doi:10.1016/j.imlet.2022.01.002 · Cited by 7

Distinctive Roles of Furin and TMPRSS2 in SARS-CoV-2 Infectivity

Essalmani, R., Jain, J., Susan‐Resiga, D., Andréo, U., Evagelidis, A., Derbali, R. M., Huynh, D. N., Dallaire, F., Laporte, M., Delpal, A., et al. (2022) · Journal of Virology · doi:10.1128/jvi.00128-22 · Cited by 194

Potential therapeutic approaches for the early entry of SARS-CoV-2 by interrupting the interaction between the spike protein on SARS-CoV-2 and angiotensin-converting enzyme 2 (ACE2)

Xiang, Y., Wang, M., Chen, H., & Chen, L. (2021) · Biochemical Pharmacology · doi:10.1016/j.bcp.2021.114724 · Cited by 24

Structure–Activity‐Related Analysis of ACE Inhibitory Peptides Against Furin: A Dual‐Action Therapeutic Approach Against SARS‐CoV‐2

Rodhi, A. M., Yap, P., & Gan, C. (2025) · Peptide Science · doi:10.1002/pep2.70013

Why All the Fury over Furin?

Osman, E. E. A., Rehemtulla, A., & Neamati, N. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c00518 · Cited by 54